The next review
Agree on the next check-in.
Ask when the person treating you will next review the plan and what they will use to judge it.
Ask who handles a refill and whether it depends on another visit or test.
Write down how to arrange that review before leaving the visit.
Between visits
Know who replies to a question.
In guidance checked September 17, 2026, the Food and Drug Administration (FDA) flags weight-care services where patients cannot contact a licensed doctor after delivery.
FDA is the US drug agency.
Ask how to reach the person who wrote your prescription and how quickly a reply is expected.
Ask who handles questions about the medicine’s label or the delivery.
Storage and delivery
Read instructions for the actual product.
Storage information checked September 17, 2026 shows different rules for different peptide medicines.
Some approved peptide medicines are stored at room temperature; others need refrigeration.
Follow the label for your medicine and ask the pharmacy that supplied it about anything unclear.
The term GLP-1 refers to a group of medicines for diabetes and weight care.
FDA advises against using delivered GLP-1 injections if they arrived warm or were not kept cool enough.
Ask the pharmacy how to handle a delivery problem.
Unclear instructions
Get the label explained.
Compounded means made or changed to meet a patient’s medical need.
FDA has received reports of people using the wrong amount of compounded semaglutide. Some reports involved hospital care. This information was checked September 26, 2026.
If instructions are unclear, have the pharmacist or the person who issued your prescription explain them before you act.
Bring the label to that conversation.
Reporting a problem
Patients can send a report to FDA.
MedWatch is FDA’s reporting service for problems with medical products.
Patients can file reports directly, according to information checked September 17, 2026.
A report by itself is not proof that a medicine caused the problem.
Open FDA’s patient reporting page